CRD-4730 / Cardurion - LARVOL DELTA

CALIBRATE-HF: A Trial of CRD-4730 in HFrEF (clinicaltrials.gov) - P2 | N=525 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

A Phase 2 Study of CRD-4730 in CPVT (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Ventricular Tachycardia

A Phase 2 Study of CRD-4730 in CPVT (clinicaltrials.gov) - P2 | N=12 | Not yet recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Trial completion date: Sep 2026 ➔ Apr 2027 | Initiation date: May 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2026 ➔ Apr 2027

Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Ventricular Tachycardia

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (clinicaltrials.gov) - P2 | N=7 | Terminated | Sponsor: Cardurion Pharmaceuticals, Inc. | N=12 ➔ 7 | Trial completion date: Sep 2025 ➔ May 2025 | Recruiting ➔ Terminated; The early termination of the clinical trial is due to an internal administrative and business decision, the study is not being terminated for safety reasons.

Enrollment change • Trial completion date • Trial termination • Cardiovascular • Heart Failure • Ventricular Tachycardia • RYR2

Effectiveness of CRD-4730 in Participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Trial completion date: Dec 2024 ➔ Sep 2025 | Trial primary completion date: Nov 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • Ventricular Tachycardia • RYR2

Effectiveness of Repeat-dose CRD-4730 in Participants with CPVT (clinicaltrials.gov) - P2 | N=12 | Not yet recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.

New P2 trial • Cardiovascular • Ventricular Tachycardia

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting | Phase classification: P2a ➔ P2

Enrollment open • Phase classification • Cardiovascular • Heart Failure • Ventricular Tachycardia • RYR2

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (clinicaltrials.gov) - P2a | N=12 | Not yet recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.

New P2a trial • Cardiovascular • Heart Failure • Ventricular Tachycardia • RYR2